Meet Pharmidex at KTN 2016
June 14, 2016

Collaboration opportunities in regenerative medicine

Pharmdiex will be attending the Innvoate UK KTN 2016 meeting focused on New Collaboration Opportunities in Regenerative Medicine.

The KTN in collaboration with Innovate UK, Cell and Gene Therapy Catapult, Department of Health and Kings College London are holding an event focussing on new unmet clinical needs, latest developments in regulatory environment and clinical adoption. Following recent developments and the UK’s Regenerative Medicine Expert Group report recommendations, this event will bring together the UK regenerative medicine communities involving industrialists, academics and clinicians from a number of clinical specialities.


The UK is leading the field in the development of cell and gene therapies. The regulatory system now has a number of mechanisms to accelerate the progress of promising therapies including EAMS and the proposed new PRIME scheme. However, practical challenges still exist to the clinical adoption of these new therapies and getting them to patients, including generating sufficient clinical data, achieving reimbursement and embedding therapies in existing or new clinical pathways).


Leading clinicians and experts from a number of organisations will be presenting at this event. Directors and managers from major funding organisations, e.g. Innovate UK, Research Councils, relevant charities will also be invited to support this event.


The main aims of this event are as follows;


  • To discuss challenges affecting clinical adoption of cell and gene-based therapies.
  • Facilitate new clinician/industry collaborations in a number of areas of clinical specialities.
  • Identify barriers to innovation and commercialisation.
  • Review current funding opportunities and identify funding gaps.
  • Provide networking opportunities to identify collaborating partners.
  • Review supporting mechanisms available to accelerate innovation and commercialisation through KTN and partners Innovate UK, Cell and Gene Therapy Catapult organisations.
  • Review current pre-clinical and clinical trials and identify best practice to accelerate regulatory approvals


For more information please see the following link: https://www.eventbrite.co.uk/e/new-collaboration-opportunities-in-regenerative-medicine-tickets-24454460951

January 15, 2026
Pharmidex offers a broad range of pre-clinical respiratory disease models to support drug discovery and development across multiple pulmonary indications. Our capabilities include validated models for asthma (acute, chronic and severe/exacerbation), cough, idiopathic pulmonary fibrosis (IPF), acute lung injury/ARDS, respiratory infections, COPD and allergic rhinitis. These models incorporate clinically relevant triggers and well-established positive controls, enabling robust and translational assessment of novel therapeutics. Our integrated respiratory platforms are designed to help accelerate informed decision-making from early research through to advanced pre-clinical development. If you are developing new therapies for respiratory diseases, we would be pleased to discuss how Pharmidex can support your programme. ๐ŸŒ www.pharmidex.com
January 14, 2026
At Pharmidex , we offer In Vivo (Non-GLP & GLP), In Vitro, and Organ-on-Chip toxicology, alongside our full range of non-GLP and GLP toxicology studies delivered in the UK, with quick turnaround times and UK-competitive pricing. Our experienced team supports your programme from study design through delivery, helping you generate high-quality, decision-ready data efficiently and cost-effectively. ๐Ÿ“ UK-based studies โšก Rapid timelines ๐Ÿ’ท Competitive pricing ๐Ÿงช In Vivo (Non-GLP & GLP), In Vitro & Organ-on-Chip toxicology Learn more: www.pharmidex.com
January 8, 2026
We’re pleased to share that Martin Barrett from Pharmidex will be attending the R SC-BMCS Postgraduate Symposium XIX – Biological and Medicinal Chemistry Symposium for Postgraduates. ๐Ÿ“… Thursday 8th January 2026 ๐Ÿ“ MIB Building, Manchester Martin will be presenting at the symposium and representing Pharmidex to discuss our services and capabilities in drug discovery and development. He would be delighted to meet and chat with attendees, explore new ideas, and discuss potential collaborations and partnerships. If you’re attending, please come and say hello! ๐ŸŒ www.pharmidex.com ๐Ÿ”— https://www.rscbmcs.org/events/psxix/
More Posts